Irritable Bowel Syndrome - Drug Pipeline Landscape, 2023

Irritable Bowel Syndrome - Drug Pipeline Landscape, 2023

Irritable bowel syndrome (IBS) is a group of symptoms related to functional gastrointestinal disorder characterized by uncomfortable abdominal pain and changes in the bowel movements. IBS classified into four main types based on the type of bowel movement which includes diarrhoea, constipation, in curtain conditions both are common or neither occurs very often (IBS-D, IBS-C, IBS-M/IBS-A, or IBS-U, respectively). IBS previously referred as spastic or nervous colon and spastic bowel.

The exact cause of IBS is not known. The cause many be due to combinations of gut-brain axis problems, gut motility disorders, pain sensitivity, infections including small intestinal bacterial overgrowth, neurotransmitters, genetic factors and food sensitivity.

The symptoms of IBS are abdominal pain or discomfort along with cramping or bloating with frequent diarrhoea or constipation and also change in bowel habits. The other symptoms of IBS incudes gastroesophageal reflux relating to genitourinary system, fibromyalgia, headache, backache and along with psychiatric symptoms such as depression and anxiety. One third of adults reporting sexual dysfunction, typically in the form of a reduction in libido.

There is no specific laboratory testing or imaging for irritable bowel syndrome. The diagnosis is based on symptoms, performance of specific investigations to rule out organic diseases which present similar symptoms. Basic investigations performed including stool microscopy and culture, blood tests, abdominal ultrasound, endoscopy, biopsies and hydrogen breath testing.

There are number of treatments which are found to be effective including psychotherapy, fiber therapy, antispasmodic and also antidepressant medication, peppermint oil, respectively.

Major pharmaceutical companies are involved in the development of potential drug candidates to improve the treatment of irritable bowel syndrome treatment such as Eluxadoline, Linaclotide, Tenapanor, and others. Key players involved in the development of therapies to treat Irritable Bowel Syndrome are HK inno.N Corp, 4D pharma, Abbvie, and others. Three drugs are under late-stage Phase III clinical trials and six drugs are in Phase II clinical trials and some other drugs are under Phase I, preclinical and discovery stages of development.

Report Highlights

Global Insight Service's, Irritable Bowel Syndrome - Drug Pipeline Landscape, 2023 report provides an overview of the Irritable Bowel Syndrome pipeline drugs. This report covers detailed insights on Irritable Bowel Syndrome drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Irritable Bowel Syndrome pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.